Mouse models and CRO selection critical to de-risking neurology drug development

GemPharmatech, a preclinical CRO specializing in mouse model creation, asserts that upstream decisions in vivo modeling are pivotal to avoiding downstream failures in CNS drug development. The company emphasizes the importance of understanding disease progression at the cellular or circuit level and the impact of a therapy on the disease course, as traditional mouse models often fail to capture the complexity and late-onset progression of neurological disorders.

To address this, GemPharmatech develops models with humanized transferrin receptor, CD98HC, and IGF-1R to facilitate brain delivery and bridge the species mismatch between mouse and human proteins. Additionally, GemPharmatech has created the FAD3T mouse model to replicate the amyloid and tau pathology found in familial Alzheimer's disease, alongside human MAPT/Tau transgene, providing a more accurate representation of the disease.

By using these advanced models, researchers can gain valuable insights into the therapeutic candidate's efficacy, biomarker shifts, and overall impact on the disease, ultimately increasing the likelihood of successful clinical trials.